Pancreatic intraepithelial neoplasia: Precursors to pancreatic cancer;Forstadier til kreft i bukspyttkjertelen

Tidsskrift for den Norske Laegeforening

Volumn 126, Issue 7, 2006, Pages 905-908

  Søreide, Kjetil ^a   Immervoll, Heike ^b   Molven, Anders ^b  

^a Avdeling for patologi   (Norway)

^b HAUKELAND UNIVERSITY HOSPITAL   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

TELOMERASE; TUMOR MARKER;

ARTICLE; CANCER; CONTROLLED STUDY; HUMAN; MEDICAL LITERATURE; MEDLINE; MICROBIOLOGY; ONCOGENE; PANCREAS; PANCREAS TUMOR; TELOMERE; TUMOR SUPPRESSOR GENE; ADENOCARCINOMA; CLASSIFICATION; DISEASE COURSE; GENETICS; PANCREAS CARCINOMA; PATHOLOGY; PRECANCER; PROGNOSIS; REVIEW;

ADENOCARCINOMA; CARCINOMA, PANCREATIC DUCTAL; DISEASE PROGRESSION; GENES, TUMOR SUPPRESSOR; HUMANS; PANCREATIC NEOPLASMS; PRECANCEROUS CONDITIONS; PROGNOSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 33645636446     PISSN: 00292001     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (36)

1. Li D, Xie K, Wolff R et al. Pancreatic cancer. Lancet 2004; 363: 1049-57.
2. Klöppel G, Hruban R, Longnecker DS et al. Tumours of the exocrine pancreas. I: Hamilton S, Aaltonen L, red. World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of the Digestive System. Lyon: IARC Press, 2000: 219-51.
3. Bardeesy N, DePinho RA. Pancreatic cancer biology and genetics. Nat Rev Cancer 2002; 2: 897-909.
4. Yan L, McFaul C, Howes N et al. Molecular analysis to detect pancreatic ductal adenocarcinoma in high-risk groups. Gastroenterology 2005; 128: 2124-30.
5. Carpelan-Holmstrom M, Nordling S, Pukkala E et al. Does anyone survive pancreatic ductal adenocarcinoma? A nationwide study re-evaluating the data of the Finnish Cancer Registry. Gut 2005; 54: 385-7.
6. Tsiotos GG, Farnell MB, Sarr MG. Are the results of pancreatectomy for pancreatic cancer improving? World J Surg 1999; 23: 913-9.
7. Nitecki SS, Sarr MG, Colby TV et al. Long-term survival after resection for ductal adenocarcinoma of the pancreas. Is it really improving? Ann Surg 1995; 221: 59-66.
8. Takaori K, Hruban RH, Maitra A et al. Pancreatic intraepithelial neoplasia. Pancreas 2004; 28: 257-62.
9. Hruban RH, Takaori K, Klimstra DS et al. An illustrated consensus on the classification of pancreatic intraepithelial neoplasia and intraductal papillary mucinous neoplasms. Am J Surg Pathol 2004; 28: 977-87.
10. Kern S, Hruban R, Hollingsworth MA et al. A white paper: the product of a pancreas cancer think tank. Cancer Res 2001; 61: 4923-32.
11. Hruban RH, Adsay NV, Albores-Saavedra J et al. Pancreatic intraepithelial neoplasia: a new nomenclature and classification system for pancreatic duct lesions. Am J Surg Pathol 2001; 25: 579-86.
12. Hruban RH, Goggins M, Parsons J et al. Progression model for pancreatic cancer. Clin Cancer Res 2000; 6: 2969-72.
13. Wilentz RE, Iacobuzio-Donahue CA, Argani P et al. Loss of expression of Dpc4 in pancreatic intraepithelial neoplasia: evidence that DPC4 inactivation occurs late in neoplastic progression. Cancer Res 2000; 60: 2002-6.
14. van Heek NT, Meeker AK, Kern SE et al. Telomere shortening is nearly universal in pancreatic intraepithelial neoplasia. Am J Pathol 2002; 161: 1541-7.
15. Tomaszewska R, Okon K, Nowak K et al. HER-2/ Neu expression as a progression marker in pancreatic intraepithelial neoplasia. Pol J Pathol 1998; 49: 83-92.
16. Tomaszewska R, Karcz D, Stachura J. An immunohistochemical study of the expression of bcl-2 and p53 oncoproteins in pancreatic intraepithelial neoplasia and pancreatic cancer. Int J Pancreatol 1999; 26: 163-71.
17. Thayer SP, di Magliano MP, Heiser PW et al. Hedgehog is an early and late mediator of pancreatic cancer tumorigenesis. Nature 2003; 425: 851-6.
18. Maitra A, Ashfaq R, Gunn CR et al. Cyclooxygenase 2 expression in pancreatic adenocarcinoma and pancreatic intraepithelial neoplasia: an immunohistochemical analysis with automated cellular imaging. Am J Clin Pathol 2002; 118: 194-201.
19. Maitra A, Adsay NV, Argani P et al. Multicomponent analysis of the pancreatic adenocarcinoma progression model using a pancreatic intraepithelial neoplasia tissue microarray. Mod Pathol 2003; 16: 902-12.
20. Luttges J, Neumann S, Jesnowski R et al. Lack of apoptosis in PanIN-1 and PanIN-2 lesions associated with pancreatic ductal adenocarcinoma is not dependent on K-ras status. Pancreas 2003; 27: e57-62.
21. Klein WM, Hruban RH, Klein-Szanto AJ et al. Direct correlation between proliferative activity and dysplasia in pancreatic intraepithelial neoplasia (PanIN): additional evidence for a recently proposed model of progression. Mod Pathol 2002; 15: 441-7.
22. Goggins M, Hruban RH, Kern SE. BRCA2 is inactivated late in the development of pancreatic intraepithelial neoplasia: evidence and implications. Am J Pathol 2000; 156: 1767-71.
23. Brat DJ, Lillemoe KD, Yeo CJ et al. Progression of pancreatic intraductal neoplasias to infiltrating adenocarcinoma of the pancreas. Am J Surg Pathol 1998; 22: 163-9.
24. Klimstra DS, Longnecker DS. K-ras mutations in pancreatic ductal proliferative lesions. Am J Pathol 1994; 145: 1547-50.
25. Johns Hopkins Pancreas Cancer Web: http://pathology. jhu.edu/n.web?EP= N&FL=PANCREAS_PANIN (12.10.2005).
26. Prasad NB, Biankin AV, Fukushima N et al. Gene expression profiles in pancreatic intraepithelial neoplasia reflect the effects of Hedgehog signaling on pancreatic ductal epithelial cells. Cancer Res 2005; 65: 1619-26.
27. Iacobuzio-Donahue CA, Maitra A, Shen-Ong GL et al. Discovery of novel tumor markers of pancreatic cancer using global gene expression technology. Am J Pathol 2002; 160: 1239-49.
28. Cao D, Maitra A, Saavedra JA et al. Expression of novel markers of pancreatic ductal adenocarcinoma in pancreatic nonductal neoplasms: additional evidence of different genetic pathways. Mod Pathol 2005; 18: 752-61.
29. Argani P, Rosty C, Reiter RE et al. Discovery of new markers of cancer through serial analysis of gene expression: prostate stem cell antigen is overexpressed in pancreatic adenocarcinoma. Cancer Res 2001; 61: 4320-4.
30. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000; 100: 57-70.
31. Lohr M, Kloppel G, Maisonneuve P et al. Frequency of K-ras mutations in pancreatic intraductal neoplasias associated with pancreatic ductal adenocarcinoma and chronic pancreatitis: a meta-analysis. Neoplasia 2005; 7: 17-23.
32. McCarthy DM, Brat DJ, Wilentz RE et al. Pancreatic intraepithelial neoplasia and infiltrating adenocarcinoma: analysis of progression and recurrence by DPC4 immunohistochemical labeling. Hum Pathol 2001; 32: 638-42.
33. Hustinx SR, Leoni LM, Yeo CJ et al. Concordant loss of MTAP and p16/CDKN2A expression in pancreatic intraepithelial neoplasia: evidence of homozygous deletion in a noninvasive precursor lesion. Mod Pathol 2005; 18: 959-63.
34. Aguirre AJ, Bardeesy N, Sinha M et al. Activated Kras and Ink4a/Arf deficiency cooperate to produce metastatic pancreatic ductal adenocarcinoma. Genes Dev 2003; 17: 3112-26.
35. Argani P, Iacobuzio-Donahue C, Ryu B et al. Mesothelin is overexpressed in the vast majority of ductal adenocarcinomas of the pancreas: identification of a new pancreatic cancer marker by serial analysis of gene expression (SAGE). Clin Cancer Res 2001; 7: 3862-8.
36. Adsay NV, Merati K, Andea A et al. The dichotomy in the preinvasive neoplasia to invasive carcinoma sequence in the pancreas: differential expression of MUC1 and MUC2 supports the existence of two separate pathways of carcinogenesis. Mod Pathol 2002; 15: 1087-95.